Microsoft word - tony_hayek_cv.doc

CURRICULUM VITAE
Tony Hayek, M.D.
DATE of BIRTH: March
PLACE of BIRTH: Haifa,
ADDRESS:

ACADEMIC DEGREES
Hadassah Hebrew University, Jerusalem, M.D.
ACADEMIC APPOINTMENTS
Head, Dept. Internal Medicine E, Rambam Medical Center Acting Dept. Head, Emergency Room, Rambam Medical Center Acting Head, Dept. Internal Medicine E, Rambam Medical Center Deputy Head, Dept. Internal Medicine E, Rambam Medical Center Senior Lecturer, Technion-Israel Institute of Technology, Associate professor, Technion-Israel Institute of Technology,
PROFESSIONAL EXPERIENCE
2004 Sabbatical – Steve Humphries, University College London, Center for cardiovascular genetics. Charles H. Revson Fellow in Biomedical Research, The Rockefeller University, New York, New York Postdoctural Associate, The Rockefeller University, Laboratory of Biochemical Genetics and Metabolism, Rambam Medical Center, Haifa, Residency in Internal Medicine Rambam Medical Center, Haifa, Internship RESEARCH INTERESTS
Effect of drugs and nutrients on the progression as well as the regression of atherosclerosis in the unique apo E deficient mouse.
TEACHING EXPERIENCE
Medical students in clerkship, 4thand 6th years. Frontal lectures to Touro College students.
MEMBERSHIP IN PROFESSIONAL SOCIETIES
European Atherosclerosis Society
A member of the residency inspection committee of the scientific council - 2004
AWARDS
International Forum on Angiotensin II Receptor Antagonism. 1999. Losartan attenuates atherosclerosis in apo E deficient mice without blood pressure reduction. Monte-Carlo, Monaco. $1500. 1998. The effect of losartan on the susceptibility of plasma LDL to lipid peroxidation and on the progression of atherosclerosis in the apo E deficient mice. American Society of Hypertension meeting, New York, NY, USA. $3,500. Israel Atherosclerosis Society Award. 1998. The effect of fosinopril and losartan on the susceptibility of LDL to oxidation and on the progression of atherosclerosis in the apo E deficient mice. The Israel Medical Association Society for Research, Prevention and Treatment of Atherosclerosis 2,000 NIS. 60th Anniversary celebration of Rambam Medical Center. 1998. The effect of high and low dose fosinopril and losartan on LDL oxidation and on the progression of atherosclerosis in apo E deficient mice. Award on oral presentation on the 60th celebration conference in Rambam Medical Center. Experimental Biology Losartan Travel Awards. 1997. The effect of the ACE inhibitor, fosinopril, and the angiotensin receptor antagonist, losartan, on the susceptibility of plasma and LDL to lipid peroxidation in the apo E deficient mice. Pharmacology 97 meeting, San Diego, CA, USA. $1,500 Merck & Co Inc. STUDENTS
M.D. THESIS
Eyal Keidar. Comparison of the effect of the angiotensin converting enzyme inhibitor, fosinopril, and of the angiotensin receptor antagonist, losartan, on the susceptibility of plasma low density lipoprotein to lipid peroxidation. 1998. Mati Waterman. The effect of Aspirin (75mg/day) on LDL susceptibility to oxidative
modification in healthy volunteers. 1999.
BASIC SCIENCE PROJECTS OF RESIDENTS
Sakhnini Emad, MD: Losartan inhibits uptake of oxidized LDL in human monocyte-derived macrophages from patients with familial hypercholesterolemia, 1999. Raz Ayelet, MD: The effect of the ACE inhibitor ramipril on lipoprotein peroxidation and on regression of atherosclerosis in apo E deficient mice. 1999-2000. RESEARCH GRANTS
Grant-in-Aid for a multicenter study on the effect of Cerivastatin in patients with hypercholesterolemia. Bayer Company, $80,000 Grant-in-Aid for the study of the effect of Fosinopril and Losartan on LDL lipid peroxidation in apo E deficient mice. Bristol-Meyers Squibb, $25,000. Grant-in-Aid for study of the effect of garlic on atherosclerosis in apo E deficient mice. $25,000. Technion Faculty of Medicine grant. The effect of antioxidants and ACE inhibitors on lipoprotein peroxidation and atherosclerosis: studies in apo E deficient mice. 4,000 NIS. Ministry of Health grant. The effect of ACE inhibitors and dietary antioxidants on LDL lipid peroxidation in apo E deficient mice. $15,000. Grant-In-Aid for a multicenter study comparing the effects of Atorvastatin vs Simvastatin in patients with hypercholesterolemia. Merck Company. $40,000. Ministry of Health-Technion Faculty of Medicine-Rambam Medical Center grant. Incorporation of polyphenolic flavonoids into macrophages: potential role in the inhibition of foam cell formation. 15,000 NIS Grant-In-Aid for a multicenter study comparing the effects of Omapatrilat vs Losartan on left ventricular hypertrophy in patients with mild to moderate hypertension. Bristol-Meyers Squibb, $100,000. Grant-In-Aid for the study of the effect of high and low dose Losartan on attenuation of atherosclerosis in apo E deficient mice, Merck Company, $30,000. PUBLICATIONS
Tony Hayek, M.D.
Thesis: Hayek T, Popovtzer M, Wald H. 24,25(OH)2D3 enhances the calcemic effect
of 1,25-(OH)2D3. Library of Hadassah Medical School, Jerusalem. 1983. Hayek T, Popovtzer MM. 24,25(OH)2D3 enhances the calcemic effect of
1,25-(OH)2D3 Proc. Soc Exp Biol Med 180:219-223, 1985. Hayek T, Fuhrman B, Levy Y, Aviram M, Brook JG. Intralipid infusion in patients with
familial hypercholesterolemia: Effect of serum and plasma lipoproteins on platelet and on macrophage cholesterol metabolism. Atherosclerosis 81:61-69, 1990. 4. Smith JD, Plump AS, Hayek T, Walsh A, Breslow JL. High levels of human apolipo- protein E
gene expression in kidney of transgenic mice. J Biol Chem 265:14709-14712, 1990. 5. Hayek T, Chajek-Shaul T, Walsh A, Azrolan N, Breslow JL. Probucol decreases apo A-I
transport rate and increases HDL cholesteryl ester fractional catabolic rate in control and human apo A-I transgenic mice. Arterioscler Thromb 11:1295-1302, 1991. 6. Chajek-Shaul Hayek T, Walsh A, Breslow JL. Expression of the human apolipoprotein A-I
gene in transgenic mice alters high density lipoprotein (HDL) particle size distribution and diminishes selective uptake of HDL cholesteryl esters. Proc Natl Acad Sci USA 88:6731- Agellon LB, Walsh A, Hayek T, Moulin P, Jiang XC, Shelanski SA, Breslow JL, Tall AR.
Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem 266:10796-10801, 1991. 8. Hayek T, Chajek-Shaul T, Walsh A, Azrolan N, Breslow JL. Mice bearing the apolipoprotein
A-I transgene. In: Scarpelli DG, Migaki G and Pletcher JM, eds. Transgenic Animal Models in Biochemical Research, Baltimore, Maryland. p.63, 1991. 9. Hayek T, Chajek-Shaul T, Walsh A, Agellon LB, Moulin P, Tall AR, Breslow JL. An
interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein
A-I genes in transgenic mice results in a profound CETP-mediated depression of HDL
cholesterol levels. J Clin Invest 90:505-510, 1992.
10. Agellon LB, Jiang XC, Hayek T, Moulin P, Walsh A, Breslow JL, Tall AR. The impact
of human cholesteryl ester transfer protein action on lipoprotein metabolism of transgenic
mice. In: Gotto AM and Paoletti R, eds. Atherosclerosis Reviews. Proceedings of the High
Density Lipoprotein Meeting, Bellagio, Italy. 1992.
11. Aalto-Setala K, Fisher EA, Chen X, Ckajek-Shaul T, Hayek T, Zechner R, Walsh A,
Ramakrishnan R, Ginsberg HN, Breslow JL. Mechanism of hypercholesterolemia in human
apo CIII transgenic mice: Diminished VLDL fractional catabolic rate associated with increased
CIII and reduced apo E on the particles. J Clin Invest 90:1889-1900, 1992.
12. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow
JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice
created by homologous recombination in ES cells. Cell 71:343-353, 1992.
13. Hayek T, Ito Y, Azrolan N, Verdery RB, Aalto-Setala K, Walsh A, Breslow JL. Dietary
fat increases HDL levels both by increasing the TR and decreasing the FCR of HDL CE
and apo A-I: Presentation of a new animal model and mechanistic studies in human
apo A-I transgenic and control mice. J Clin Invest 91:1665-1671, 1993.
14. Hayek T, Azrolan N, Verdery RB, Walsh A, Chajek-Shaul T, Agellon LB, Tall AR,
Breslow JL. Hypertriglyceridemia and cholesteryl ester transfer protein (CETP) expression
interact to dramatically alter HDL levels, particle sizes and metabolism: Studies in transgenic
mice. J Clin Invest 92:1143-1152, 1993.
15. Hayek T, Oiknine J, Brook JG, Aviram M. Increased plasma and lipoprotein lipid peroxidation
in apo E-deficient mice. Bioch Biophys Res Comm 201:1567-1574, 1994.
16. Hayek T, Oiknine J, Brook JG, Aviram M. Role of apolipoprotein in HDL, but not in
macrophages in cellular cholesterol efflux: studies in apo E knockout transgenic mice.
Bioch Biophys Res Comm. 205:1072-1078, 1994.
17. Shachter
Hayek T, Leff T, Smith JD, Rosenberg D, Walsh A, Ramakrishnan R,
Goldberg IJ, Ginsberg HN, Breslow JL. Oxerexpression of apo C II causes hyper-
triglyceridemia in transgenic mice. J. Clin Invest 93:1683-90, 1994.
18. Hayek T, Oiknine J, Dankner G, Brook JG, Aviram M. HDL apolipoprotein A-I
attenuates oxidative modification of low density lipoprotein: Studies in transgenic mice.
Eur J Clin Chem Clin Biochem 33:721-725, 1995.
19. Aviram M, Maor I, Keidar S, Hayek T, Oiknine J, Bar-El Y, Adler Z, Kertzman V, Milo
S. Biochem Biophys Res Comm 216:501-513, 1995.
20. Huang L, Voyiuziakis E, Markenson D, Sokol K, Hayek T, Breslow JL. Apo B gene knockout
in mice results in embryonic lethality in homozygotes and neural tube defects, male
infertility and reduced HDL cholesterol ester and apo A-I transport rates in hetrozygotes. J
Clin Invest 96:2152-2161, 1995.
21. Hayek T, Masucci-Magoules L, Jiang X, Walsh A, Rubin Ed, Breslow JL, Tall AR. 1995.
Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing CETP
transgene. J Clin Invest 96:2071-2074
22. Coleman R, Mazor L, Shenzer P, Aviram M, Keidar S, Hayek T. Pathogenesis of
atherosclerosis. Rev Acta Histochemica 98:372, 1996.
23. Hayek T, Rosenblat M, Aviram M. Increased platelet activation in the atherosclerotic
apolipoprotein E-deficient transgenic mice: role of plasma lipoproteins and platelet
composition. Eur J Lab Med. 4:79-84, 1996
24. Keidar S, Attias J, Smith J, Breslow JL, Hayek T. The angiotensin II receptor antagonist,
losartan, inhibits LDL lipid peroxidation and atherosclerosis in apo E deficient mice.
Bioch Biophy Res Comm. 236:622-625, 1997.
25. Aviram
Hayek T, Furman B. Red wine consumption inhibits LDL oxidation and
aggregation in humans and in atherosclerotic mice. Bio Factors 6:415-419, 1997.
26. Fuhrman B, Ben-Yaish L, Attias J, Hayek T, Aviram M. Tomato lycopene and β-carotene
inhibit LDL oxidation and this effect depends on the lipoprotein vitamin E content.
Nutr Metab Cardiovasc Dis 7:433-443, 1997.
27. Maor
Hayek T, Coleman R, Aviram M. Plasma LDL oxidation leads to its aggregation
in the atherosclerotic apo E deficient mice. Arterioscler Thromb 17:2995-3005, 1997.
28. Weinstock P, Bisgaier C, Hayek T, Aalto-Setala K, Sehayek E, Wu L, Sheiffele P,
Markel M, Essenburg A, Breslow JL. Decreased HDL-C levels but normal lipid absorption,
growth and feeding behavior in apo A-IV knockout mice. J Lipid Res 38:1782-1794, 1997.
29. Levak-Frank S, Weinstock P, Hayek T, Verdery R, Hofmann W, Ramakrishnan R,
Sattler W, Breslow JL, Zechner R. Induced mutant mice expressing lipoprotein lipase
exclusively in muscle have subnormal triglycerides, yet reduced HDL-C levels in plasma.
J Biol Chem 272:17182-17190, 1997.
30. Tall A, Sharp D, Zhong S, Hayek T, Masucci-Magoulas L, Rubin EM, Breslow JG. Cholesteryl
ester transfer protein and atherogenesis. Ann NY Acad Sci 811:178-182, 1997.
31. Fuhrman B, Buch S, Vaya J, Belinky PA, Coleman R, Hayek T, Aviram M. Licorice extract
and its major polyphenol glabridin protect LDL against lipid peroxidation: In vitro and ex vivo
studies in humans and in atherosclerotic apo E deficient mice. Am J Clin Nutr 66:267-275,

32. Hayek T, Fuhrman B, Vaya J, Rosenblat M, Belinky P, Coleman R, Elis A, Aviram M.
Reduced Progression of atherosclerosis in the apo E deficient mice following consumption
of red wine, or its polyphenols, Quercetin or Catechin, is associated with reduced
susceptibility of LDL to oxidation and to aggregation. Arterioscler Thromb Vasc Biol
17:2744-2752, 1997.
33. Aviram M, Hussein O, Rosenblat M, Sclezinger S, Hayek T, Keidar S. Interactions of
and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-COA reductase inhibitor therapy. J Cardiovasc Pharmacol 31:39-45, 1998. 34. Zaiou M, Azrolan N, Hayek T, Wang H, Wu L, Cizman B, Madaio M, Milbrandt J, Marsh J,
Breslow J, Fisher Ed. The full induction of human apo A-I gene expression by the
experimental nephrotic syndrome in transgenic mice depends on cis-acting elements in the
proximal 256 base-pair promoter region and the transacting factor early growth response
1. J Clin Invest 101:1669-1707, 1998.
35. Hayek T, Attias J, Smith J, Breslow JL, Keidar S. Antiatherosclerotic and antioxidative
of captopril in apo E deficient mice. J Cardiovasc Pharm. 31:540-544, 1998.
36. Rosenblat M, Belinky P, Vaya J, Levy R, Hayek T, Coleman R, Merehav S, Aviram M.
Macrophage enrichment with the isofluvan glabridin inhibits NADPH oxidase- induced cell-
mediated oxidation of LDL. J Biol Chem 274:13790-13799, 1999.
37. Hayek T, Attias J, Coleman R, Brodsky S, Smith J, Breslow J, Keidar S. The angiotensin
converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan,
inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure
in apolipoprotein E deficient mice. Cardiovasc Res 44:579-587, 1999.
38. Maor I, Kaplan M, Hayek T, Vaya J, Hofman A, Aviram M. Oxidized monocyte-derived
macrophages in aortic atherosclerotic lesion from apo E deficient mice and from human
artery contain lipid peroxide and oxysterols. Biochem Biophys Res Comm 269:775-780, 2000. 39. Maor Hayek T, Hirsh M, Iancu I, Aviram M. Macrophage-released proteoglycans enhance
LDL aggregation: studies in aorta from apo E-deficient mice. Atherosclerosis 150:91-101,
40. Fuhrman B, Rosenblatt M, Hayek T, Coleman R, Aviram M. Ginger extract consumption
reduces plasma cholesterol, inhibits LDL oxidation and attenuates development of
in atherosclerotic apo E deficient mice. J Nutr 130:1124-1131, 2000.
41. Keidar S, Attias J, Coleman R, Wirth K, Scholkens B, Hayek T. Attenuation of
atherosclerosis in apo E deficient mice by ramipril is dissociated from its
antihypertensive effects and from potentiation of bradykinin. J Cardiovasc Pharmacol
35:64-72, 2000.
42. Hayek T, Aviram M, Heinrich R, Sakhnini E, Keidar S. Losartan inhibits cellular uptake of
oxidized LDL in monocyte-macrophages from hypercholesterolemic patients. Biochem
Biophys Res Comm, 273:417-470, 2000.
43. Keidar S, Heinrich R, Kaplan M, Hayek T, Aviram M. Angiotensin II administration to
Atherosclerotic mice increases macrophage uptake of oxidized LDL. A possible role for Interleukin-6. Arterioscler Thromb Vasc Biol. 21:1464-1469,2001.
44. Kaplan M, Hayek T, Raz A, Coleman R, Dornfeld L, Vaya J, Aviram M. Pomegranate
juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation,
cellular cholesterol accumulation and development of atherosclerosis. J Nutr. 131:2082-
2089, 2001.
45. Vaya J, Aviram M, Mahmood S, Hayek T, Grenadir E, Hoffman A, Milo S. Selective
Distributionof oxysterols in atherosclerotic lesions and human plasma lipoproteins. Free Radic Res. 34:485-97,2001 46. Aviram M, Dornfeld L, Kaplan M, Coleman R, Gaitini D, Nitecki S, Hofman A,
Rosenbtal M, Volkova N, Presser D, Attias J, Hayek T, Fuhrman B.
Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: studies-in atherosclerotic mice and in humans. Drugs Exp Clin Res 28:49- 62, 2002 . 47. Rosenblat M, Grunfeld O, Hayek T, Aviram M. Serum paraoxonase activity and extent of
lipid peroxidation are not affected by increased levels of human apolipoprotein A-I:
studies in transgenic mice. Clin Chem Lab Med 40:9-14,2002.
48. Fuhrman B, Volkova N, Kaplan M, Attias J, Hayek T, Aviram M. Antiatherosclerotoc
effects of licorice extract supplementation on hypercholesterolemic patients: increased
resistance of LDL to atherogenic modifications, reduced plasma lipid levels, and
decreased systolic blood pressure. Nutrition 18:268-73, 2002.
49. Hayek T, Kaplan M, Raz A, Keidar S, Coleman R, Aviram M. Ramipril administration to
atherosclerotic mice reduce oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis. Atherosclerosis 161:65-74, 2002. 50. Fuhrman B, Koren L, Volkova N, Keidar S, Hayek T, Aviram M. Atrovastatin therapy in
hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 164:179-85,2002. 51. Coleman R, Hayek T, Keidar S, Aviram M. Atherosclerosis: The Apolipoprotein E-deficient
mouse model revisited. Microscopy and Microanalysis, Volume 8, Sopplement 2:944-945,
52. Shamir R, Shehadeh N, Rosenblat M, Eshach-Adiv O, Coleman R, Kaplan M, Hamoud S, Lischinsky S, Hayek T. Oral insulin supplementation attenuates atherosclerosis
progression in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 23:104-
10,2003

53. Keidar S, Hayek T, Kaplan M, Pavlotzky E, Hamoud S, Coleman R, Aviram M. Effect of
Eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc pharmacol 41:955-963,2003 54. Hayek T, Hamoud S, Keidar S, Pavlotzky E, Coleman R, Aviram M, Kaplan M. Omapatrilat
decreased macrophage oxidative status and atherosclerosis progression in
atherosclerotic apolipoprotein E-deficient Mice. Cardiovasc Pharmacol 43:140-147, 2004
55. Hayek T, Pavlotzky E, Hamoud S, Coleman R, Keidar S, Aviram M, Kaplan M. Tissue
Angiotensin- Converting-Enzyme (ACE) deficiency leads to a reduction in oxidative
stress and in atherosclerosis. Studies in ACE-Knockout mice type 2. Arterioscler Thromb
Vasc Biol 23:2090-2096, 2003
56. Rosenblat M, Hayek T, Hussein K, Aviram M. Decreased macrophage Paraoxonase 2
expression in patients with hypercholesterolemia is the result of their increased
cellular cholesterol content: Effect of Atorvastatin therapy. Arterioscler Thromb Vasc
Biol 24:175-180, 2004.
57. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosteron
administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development. A possible role for Angiotensin-Converting Enzyme and the receptors for Angiotensin II and Aldosterone. Circulation, 109:2213-2220, 2004. 58. Hayek T, Hussein K, Aviram M, Coleman R, Keidar S, Pavlotzky E, Kaplan M.
Macrophage-derived foam cell formation in streptozoticin-induced diabetic mice:
Stimulatory effect of Glucose. Atherosclerosis, 2005 nov; 183:25-33.
59. Hayek T, Stephens J.W, Hubbart C.S, Acharya J, Caslake M.J, Hawe E, Miller G.J,
Hurel S.J, Humphries S. A common variant in the glutathione S transferase gene is
associated with elevated markers of inflammation and lipid peroxidation in subjects
with diabetes mellitus. Atherosclerosis. 184:404-412, 2006.
60. Luigi Fabrizio Rodella, Francesca Bonomini, Rita Rezzani, Sandra Tengattini, Tony Hayek,
Michael Aviram, Shlomo Keidar, Raymond Coleman, Rossella Bianchi. Atherosclerosis and
the protective role played by different proteins in apolipoprotein E-deficient mice. In press,
2006.
61. Coleman R, Hayek T, Keidar S, Aviram M. A mouse model for human atherosclerosis: Long -
term histopathological study of lesion development in the aortic arch of apolipoprotein E –
deficient (E°) mice. Acta histochemica, 108: 415-424, 2006.
CASE REPORTS
Nagler A, Brenner B, Hayek T, Brook JG. Subdural hemorrhage in a 32-year old man with
chronic idiopathic thrombocytopenic pupura. Acta Hemat 75:186-187, 1986.
Benderly A, Shehadeh N, Griff Z, Hayek T, Erde P, Etzioni A. Bacterial meningitis in infants
two to six weeks old. Helv Pediat Acta 41:311-315, 1986.
Hayek T, Brook JG. Q-fever endocarditis. Harefuah 113:108-109, 1987.
Hayek T, Finkelstein R. Non-tropical pyomyositis in an elderly patient. Harefuah
Hayek T, Kleinhaus U, Hashmonai M, Keidar S. Preoperative diagnosis of Mirizzi syndrome.
Am J Med Sci 296:74-75., 1988.
Hayek T, Brenner B, Eidelman S. Recurrent spontaneous bacterial peritonitis in a
patient with polycythemia vera. Am J Hematol 29:54-55, 1988. Hayek T, Markel A, Goldfed M, Ben-Arie Y, Brook JG. Chronic active hepatitis presenting as
retroperitoneal lymphadenopathy. Postgrad Med J 70:380-382, 1994.
Hayek T, Markel A, Karban A, Finkelstein R. Left sided group A streptococal endocarditis in
an intravenous drug abuser with mitral valve prolapse. Harefuah 126:251-252, 1994.
Hayek T, Finkelstein R. Sarcoidosis mimicking toxoplasmosis with severe
hypercalcemia and normal 1,25-dihydroxy vitamin D. J Int Med 240:165-167, 1996. Hayek T, Gallimidi Z, Yassin K, Brook G. Transient radiologic and colonoscopic
features of inflamatory bowel disease in a patient with severe salmonella gastroenteritis. Am J Gastroentrol 92(2):349-351, 1997. 11. Avivi I, Valfsons S, Finkelstein R, Hayek T, Brook JG. Pulmonary infiltrates and skin lesions.
12. Hayek
T, Engel A, Eyal A, Brook JG. Abdominal retroperitoneal lymphadenopathy in an
elderly man. Postgrad Med J 73:591-592, 1997. Hayek T, Munichor M, Michaelson M, Best LA, Bentur L. Fat Embolism in a boy
with minor non-fracture trauma. Pediat Pulmon J 27:221-223, 1999. 14. Soudack M, Shechter A, Malkin L, Hayek T, Gaitini D. Inflammatory pseudotumor of the liver:
sonographic and computed tomographic features with complete regression. J Ultrasound Med 19:501-4, 2000. 15. Hamoud S, Nitesky S, Engel A, Goldsher D, Hayek T. A case report of hyoplasia of the
inferior vena cava with azygous continuation presenting as recurrent leg deep vein thrombosis. Am J Med Sci 319:414-6,2000. 16. Raz A, Bergman R, Eilam O, Yungerman T, Hayek T. Olanzapine Induced Hypersensitivity
Syndrome. Am J Med Sci. 321:156-8, 2001. 17. Dagash M, Nakhoul F, Daoud D, Hayek T. The spectrum of “cerebral
hyponatremia”—cerebral salt wasting syndrome in a patient with pituitary adenoma. Isr Med Assoc J 2:865-7, 2000. Hayek T, Keidar S. Acute gastroenteritis caused by enterohemorrhagic E
coli O157:H7. Harefuah 15;134(10):767-9, 831,1998. Hayek T, Muchnik L, Bergman R. Acute Rhabdomyolysis
Myoglobinuria associated with isotretinoin treatment. Intern J of Derm. 42:499-500,2003 20. Zalts R, Hamoud S, Bar-Shalom R, Eilam O, Rozin A, Hayek T. Aortitis: Presenting
as fever of unknown origin – FDG PET for diagnosis and follow up.
Annual European Congress of Rheumatology EULAR, Vienna, Austria, 2005.
21. Hussein K, Hayek T, Yassin K, Fischer D, Vlodavsky E, Kra-Oz Z, Hamoud S.
Acute CMV infection associated with the onset of inflammatory Bowel Disease. A case report & review of the literature. 2005. 22. Zalts R, Hamoud S, Bar-Shalom R, Eilam O, Rozin A, Hayek T. Panaortitis:
Diagnosis via fluorodeoxyglucose positron emission tomography. Am J Med
Sci. 2005 Nov; 330(5):247-9.
23. Hussein K, Hayek T, Yassin K, Fischer D, Vlodavsky E, Kra-Oz Z, Hamoud S.
Acute cytomegalovirus infection associated with the onset of inflammatory bowel
disease. Am J Med Sci. Jan; 331(1):40-3.
CONFERENCES
INVITED TALKS
Hayek T. Heterologous HDL in transgenic mice. American Heart Association 67th Scientific
Sessions, Anaheim, California, USA. 1991.
Hayek T. Studies of HDL metabolism in transgenic mice. European Lipoprotein Club,
Tutzing, Germany, September 1992.
Hayek T. HDL metabolism in transgenic mice. Glaxo-Group Research Cellular and Molecular
Sciences Division, London, England, September 1992.

4. Hayek T. Transgenic mice – lipoproteins and atherosclerosis. Session Chairman.
American Heart Association, 68th Scientific Sessions. Anaheim, CA, USA.
November 1995.
5. Hayek T. The effect of the ACE inhibitor, ramipril, on blood pressure, lipoprotein peroxidation
in apo E deficient mice. Hoechst Marion Roussel – Cardiovascular Research. Frankfurt, Germany. October 1998.
ABSTRACTS
Hayek T, Fuhrman B, Levy Y, Aviram M, Brook JG. Intralipid infusion in patients with familial
hypercholesterolemia: Effect of serum and plasma lipoproteins on platelet aggregation and
on macrophage cholesterol metabolism. 8th International Symposium on Atherosclerosis.
Rome, Italy, 1988.
Hayek T, Gaiteni D. Multiple myeloma presenting as bilateral high adrenal
plasma cell tumors. Israeli Pathologist Association Conference. Tel-Aviv, Israel, 1988. Hayek T, Chajek-Shaul T, Walsh A, Azrolan N, Breslow JL. Probucol reduces HDL-C levels
by decreasing apo A-I transport rate in human A-I transgenic mouse model. Circulation
82:929, 1990.
Hayek T, Walsh A, Breslow JL. Reduced fractional catabolic rate of HDL
cholesteryl ester in human A-I transgenic mice. Circulation 82:2115, 1990. Agellon LB, Walsh A, Hesler CB, Shelanski SA, Hayek T, Gillette TG, Breslow JL, Tall TG.
Expression of human cholesteryl ester protein transfer (CETP) in transgenic mice. Circulation
82:1714, 1990.
Hayek T, Chajek-Shaul T, Walsh A, Agellon LB, Moulin P, Tall AR, Breslow JL. Interaction of
human apo A-I and CETP genes in transgenic mice results in a profound decrease in HDL
cholesterol. Circulation 84:68, 1991.
Hayek T, Chajek-Shaul T, Azrolan N, Walsh A, Breslow JL. Hypertrigly-ceridemia in human
apo CIII transgenic mice causes reduced HDL-C and apo A-I levels. European
Atherosclerosis Society. Nice, France, 1992.
Hayek T, Ito Y, Verdery RB, Chajek-Shaul T, Walsh A, Breslow JL. A high fat diet
increases hepatic production of human apo A-I in transgenic mice. Circulation 86:1104, 1992. Aalto-Setala K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A,
Ramakrishnan R, Ginsberg HN, Breslow JL. Mechanism of hypertriglyceridemia in human
apo CIII transgenic mice. Circulation 86:1106, 1992.

10. Hayek T, Azrolan N, Walsh A, Chajek-Shaul T, Verdery RB, Agellon LB, Tall AR, Breslow JL.
CETP plays an important role in the inverse relationship between plasma triglycerides and HDL cholesterol levels. Circulation 86:1682, 1992.
11. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Breslow JL. Apolipoprotein E-
deficient mice created by homologous recombination in embryonic stem cells. Circulation 86:1873, 1992. Hayek T, Leff T, Smith J, Rosenberg D, Walsh A, Goldberg I, Ramakrishman R,
Ginsberg H, Breslow J 1993. Overexpression of apolipoprotein C II Cause hypertriglyceridemia in transgenic mice. Circulation 88:270, 1993.
13. Odaka H, Azrolan N, Hayek T, Aalto-Setala K, Breslow J. Increased human apo A-I
synthesis in hepatocytes of transgenic mice fed a high fat diet. Circulation 88:422, 1993.
14. Plump A, Hayek T, Walsh A, Breslow J. Diminished HDL - CE flux in apo A-I deficient
mice. Circulation 88:422, 1993.
15. Tall A, Jiang X, Quinet E, Oliveira H, Agellon L, Hayek T, Walsh A, Breslow J. Plasma
CETP in lipoprotein metabolism. 62nd European Atherosclerosis Society. Jerusalem,
Israel, 1993.
16. Hayek T, Oiknine J, Breslow J, Aviram M, Brook JG. Plasma and lipoprotein oxidation in apo
E deficient mice with severe hypercholesterolemia and atherosclerosis. Xth International Symposium on Atherosclerosis. Montreal, Canada, 1994
17. Hayek T, Keidar S, Mei Y, Oiknine J, Breslow J. Effect of Angiotensin converting enzyme
inhibitors on LDL lipid peroxidation and atherosclerosis in apo E deficient mice. Circulation 92:2998, 1995.
18. Hayek T, Rubbin E, Walsh A, Breslow J, Alan T. Decreased aortic atherosclerotic lesions in
hypertriglyceridemic mice expressing CETP. Circulation 92:359, 1995.
19. Hayek T, Rosenblat M, Aviram M. Increased platelet activation in atherosclerotic, apo E
deficient transgenic mice - Role of plasma lipoprotein and platelet composition. Circulation 92:106, 1995. Hayek T, Breslow JL. Dramatic reduction of HDL in apo A-II deficient mice
created by homologous recombination in ES cells. Circulation 92:105, 1995.
21. Hayek T, Attias J, Coleman R, Breslow J, Keidar S. The effect of the ACE inhibitor fosinopril
and the angiotensin receptor antagonist losartan on the susceptibility of plasma LDL to lipid peroxidation and on the progression of atherosclerosis in the apo E deficient mice. X1th International Symposium on Atherosclerosis. Paris, France, 1997. 22. Hayek T, Attias J, Coleman R, Keidar S. Losartan attenuates atherosclerosis in apo E
deficient mice without blood pressure reduction. International Forum on Angiotensin II Receptor Antagonism. Monte Carlo, Monaco, 1999.

23. Hayek T, Raz A, Coleman R, Heinrich R, Kaplan M. Ramipril induces regression of
the atherosclerotic lesions in apo E deficient mice. XIIth International Symposium
on Atherosclerosis. Stockholm, Sweden, 2000.
24. Coleman R, Hayek T, Keidar S, Aviram M. Atherosclerosis: The apolipoprotein E-deficient
mouse model revisited. Microscopy Society of America 8(suppl 2),2002. CLINICAL RESEARCH
1. 2000-2003 Co-Investigator, Rambam Medical Center, Pharmanet. A Multicenter Study Comparing Blood Pressure Control by Enalapril with and 2. 1999 – 2003 Co-Investigator, Rambam Medical Center, Bristol-Myres-Squibb. A Multicenter Study Comparing the Effect of Omapatrilat vs Enalapril on the Morbidity and Mortality of Patients with Severe Congestive Heart Failure. 300 3. 2003 – 2004 Co-Investigator, Rambam Medical Center, Sanofi~Synthelabo. A multicenter Survey on Clopidogrel in Non Myocardial Infarct Acute Coronary 4. 2004 – Co-Investigator, Rambam Medical Center, Novartis (Icon). A Multicenter Study Comparing the Effect of Amlodipine vs Combination of Amlodipine with Valsartan in treating moderate severity Diastolic 5. 2004 – Co-Investigator, Rambam Medical Center, BMS (PPD). A Multicenter Study Comparing the Effect of Irbesartan with or without Disothiazide in treating severe Distolic Hypertention. 60 6. Co-Investigator, Rambam Medical Center, Novartis. A Multicenter Study comparing the effect of HCTZ combination with HCTZ alone, Irbesartan and HCTZ combination, or Amlodipine and HCTZ combination. 8 7. 2005-2006 Co-Investigator, Rambam Medical Center, Novartis A Multicenter Study Randomized Double Blind, Placebo Controlled trial Comparing the Efficacy and Safety of the Combination of Aliskeren with HCTZ compared with Irbesartan or Amlodipine with HCTZ or HCTZ alone in Hypertensive Patients with BMI >=30 kg/m2 not Adequately Responsive to HCTZ 25 mg. (Incliding ICH-GCP training in investigator meeting).

Source: http://www.aviramlipids.com/Tony_Hayek_cv.pdf